Literature

  1. International Immuno-Oncology Biomarker in Breast Cancer Working Group

Publications about TILs in Breast Cancer

selection of articles from Jan 1, 2010 to Dec 6, 2017
choosen, classified & inserted into the table by Nina Radosevic-Robin
publications are presented as in the example below:

Year First author Full title Journal, year, volume, issue, pages (copy-paste from PubMed)
2010 Denkert C Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer J Clin Oncol. 2010 Jan 1;28(1):105-13.

publications are inserted by ascending publication date (from older to newer)
if a publication deals with several topics of the listed below, the publication is inserted under each topic adressed (this ensures a comprehensive bibliography for each topic)
publications of special interest are presented in bold characters

GENERAL ARTICLES and REVIEWS

 

Year First author Full title Journal, year, volume, issue, pages (copy-paste from PubMed)
2010 Andre F Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients. Curr Opin Oncol. 2010 Nov;22(6):547-51.
2011 Mouawad R Lymphocyte infiltration in breast cancer: a key prognostic factor that should not be ignored. J Clin Oncol. 2011 May 20;29(15):1935-6.
2011 DeNardo Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011 Jun;1(1):54-67.
2011 Denkert C Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy. Semin Immunopathol. 2011 Jul;33(4):341-51.
2011 Fridman WH Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 2011 Sep 1;71(17):5601-5.
2011 Curigliano Immunity and autoimmunity: revising the concepts of response to breast cancer. Breast. 2011 Oct;20 Suppl 3:S71-4.
2012 Ruffell B Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2796-801.
2012 Krell J The clinical significance of tumor infiltrating lymphoctyes in breast cancer: does subtype matter? BMC Cancer. 2012 Apr 3;12:135.
2013 Andre F Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res. 2013 Jan 1;19(1):28-33.
2013 Denkert C Diagnostic and therapeutic implications of tumor-infiltrating lymphocytes in breast cancer. J Clin Oncol. 2013 Mar 1;31(7):836-7
2013 Krüger JM Combat or surveillance? Evaluation of the heterogeneous inflammatory breast cancer microenvironment. J Pathol. 2013 Mar;229(4):569-78.
2013 Gu-Trantien C & Willard-Gallo K Tumor-infiltrating follicular helper T cells: The new kids on the block. Oncoimmunology. 2013 Oct 1;2(10):e26066.
2014 Issa-Numer Y Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy. Oncoimmunology. 2014 Feb 14;3:e27926.
2014 Denkert C The immunogenicity of breast cancer–molecular subtypes matter. Ann Oncol. 2014 Aug;25(8):1453-5.
2014 Sklan A Lymphocytes prognostic in breast cancer. Lancet Oncol. 2014 Sep;15(10):e422
2014 Savas P Oncogene addiction and immunity: clinical implications of tumour infiltrating lymphocytes in breast cancers overexpressing the HER2/neu oncogene. Curr Opin Oncol. 2014 Nov;26(6):562-7.
2014 Wesolowski R & Carson WE 3rd. Tumor Infiltrating Lymphocytes – The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast Cancer. J Carcinog Mutagen. 2014 Dec;5(6). pii: 199.
2015 Salgado R The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015 Feb;26(2):259-71.
2015 Karn T The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers. Curr Cancer Drug Targets. 2015;15(8):652-64.
2015 Azim HA Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. Breast. 2015 Jun;24(3):290-3.
2015 Ali HR PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol. 2015 Jul;26(7):1488-93.
2015 Gentles AJ The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015 Aug;21(8):938-945.
2015 Dushyanthen S Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med. 2015 Aug 24;13:202.
2015 Ahn SG Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer. J Pathol Transl Med. 2015 Sep;49(5):355-63.
2015 Ohtani H Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis. Pathol Int. 2015 Dec;65(12):644-51.
2016 Savas P Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016 Apr;13(4):228-41.
2016 Ingold-Hepner B Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer. Breast Care (Basel). 2016 Apr;11(2):96-100.
2016 Dieci MV The immune system and hormone-receptor positive breast cancer: Is it really a dead end? Cancer Treat Rev. 2016 May;46:9-19.
2016 Mani NL Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer. Breast Cancer Res. 2016 Jul 29;18(1):78.
2016 Smid  M Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nat Commun. 2016 Sep 26;7:12910.
2016 Denkert C Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol. 2016 Oct;29(10):1155-64.
2016 Stanton SE Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. JAMA Oncol. 2016 Oct 1;2(10):1354-1360.
2016 Bense RD Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. J Natl Cancer Inst. 2016 Oct 13;109(1).
2016 Stanton SE & Disis ML Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016 Oct 18;4:59.
2016 Criscitiello C Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. Cancer Treat Rev. 2016 Nov;50:205-207.
2017 Radosevic-Robin N [Evaluation of the immune infiltrate in breast cancer]. French. Bull Cancer. 2017 Jan;104(1):52-68.
2017 Burugu S Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer. 2017 Jan;24(1):3-15.
2017 Luen SJ Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology. 2017 Feb;49(2):141-155.
2017 Ravelli A Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility. Tumour Biol. 2017 Apr;39(4):1010428317695023.
2017 Dannenfelser R Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity. Oncotarget. 2017 Jul 7;8(34):57121-57133.
2017 Wein L Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. Front Oncol. 2017 Aug 3;7:156.
2017 Hendry S Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Adv Anat Pathol. 2017 Sep;24(5):235-251.
2017 Solinas C Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art. Breast. 2017 Oct;35:142-150.
2017 Dieci MV Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Semin Cancer Biol. 2017 Oct 9. doi: 10.1016/j.semcancer.2017.10.003. |Epub ahead of print] Review.
2017 Hendry S Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol. 2017 Nov;24(6):311-335.
2017 de Melo Gagliato D Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. Biochim Biophys Acta. 2017 Dec;1868(2):527-537.
2017 Solinas C Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. Front Immunol. 2017 Oct 30;8:1412. doi: 10.3389/fimmu.2017.01412. eCollection 2017.
2017 Tramm T Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists. Acta Oncol. 2017 Nov 23:1-5. doi: 10.1080/0284186X.2017.1403040. [Epub ahead of print]

Triple Negative Breast Cancer (TNBC), Early Stage, ADJUVANT Setting

Year First author Full title Journal, year, volume, issue, pages (copy-paste from PubMed)
2010 Lim KH Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast. Cancer Immun. 2010 Jan 22;10:3.
2010 de Kruijf EM The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res. 2010 Feb 15;16(4):1272-80.
2010 Bellati F Immunologic systemic effect of neoadjuvant chemotherapy requires investigation before tumor-associated lymphocytes can be introduced in breast cancer treatment algorithm. J Clin Oncol. 2010 Sep 20;28(27):e471-2; author reply e473.
2011 Yan M Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res. 2011 Apr 26;13(2):R47.
2011 Mahmoud SM An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat. 2011 May;127(1):99-108.
2011 Mahmoud SM Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011 May 20;29(15):1949-55.
2011 Baker K Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology. 2011 Jun;58(7):1107-16.
2011 Liu F CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. 2011 Nov;130(2):645-55.
2012 Liu S CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012 Mar 15;14(2):R48.
2012 Mahmoud SM The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat. 2012 Apr;132(2):545-53.
2012 Mohamed ZM The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2012 Aug 21;107(5):864-73.
2012 Liu F Peritumoral FOXP3⁺ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3⁺ regulatory T cell is prognostic predictor of breast cancer patients. Breast Cancer Res Treat. 2012 Sep;135(2):459-67.
2012 Ma C Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer. J Immunol. 2012 Nov 15;189(10):5029-36.
2013 West NR Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer. 2013 Jan 15;108(1):155-62.
2013 Loi S Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013 Mar 1;31(7):860-7.
2013 Muenst S The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013 Jun;139(3):667-76.
2013 Gu-Trantien C CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013 Jul;123(7):2873-92.
2013 Mohammed ZM The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2013 Sep 17;109(6):1676-84.
2013 de Kruijf EM Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients. Breast Cancer Res Treat. 2013 Nov;142(2):355-64.
2014 Kim S Zonal difference and prognostic significance of foxp3 regulatory T cell infiltration in breast cancer. J Breast Cancer. 2014 Mar;17(1):8-17.
2014 Chen Z Intratumoral CD8⁺ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. PLoS One. 2014 Apr 17;9(4):e95475.
2014 Schalper KA In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014 May 15;20(10):2773-82.
2014 Schalper KA PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer. Oncoimmunology. 2014 Jun 25;3:e29288.
2014 Loi S Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014 Aug;25(8):1544-50.
2014 Ali HR Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014 Aug;25(8):1536-43.
2014 Adams S Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014 Sep 20;32(27):2959-66.
2014 Liu S Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res. 2014 Sep 6;16(5):432.
2015 Quigley D Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. Mol Cancer Res. 2015 Mar;13(3):493-501.
2015 Nawaz S Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. Mod Pathol. 2015 Jun;28(6):766-77.
2015 Dieci MV Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol. 2015 Aug;26(8):1698-704.
2016 Mulligan AM Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer. Cancer Immunol Res. 2016 Jan;4(1):41-8.
2016 Park IH Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. Clin Breast Cancer. 2016 Feb;16(1):51-8.
2016 KotoulaV Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. Oncotarget. 2016 Jan 26;7(4):5074-87.
2016 Pruneri G Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. Ann Oncol. 2016 Feb;27(2):249-56.
2016 Park IH Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. Clin Breast Cancer. 2016 Feb;16(1):51-8.
2016 Matsumoto H Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer. Breast Cancer Res Treat. 2016 Apr;156(2):237-47.
2016 Lee HJ Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer. J Clin Pathol. 2016 May;69(5):422-30.
2016 Beckers RH Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology. 2016 Jul;69(1):25-34.
2016 Pruneri G Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Res Treat. 2016 Jul;158(2):323-31.
2016 Kotoula V Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes. PLoS One. 2016 Sep 29;11(9):e0163138.
2016 Li X Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer. Am J Clin Pathol. 2016 Oct;146(4):496-502.
2016 Buisseret L Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncoimmunology. 2016 Dec 14;6(1):e1257452.
2017 Chung YR Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status. Breast Cancer Res Treat. 2017 Feb;161(3):409-420.
2017 Mori H The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Oncotarget. 2017 Feb 28;8(9):15584-15592.
2017 Kim YI Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes. Virchows Arch. 2017 Apr;470(4):381-389.
2017 Green AR Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers. Cancer Immunol Res. 2017 Apr;5(4):292-299.
2017 Yeong Y Higher densities of Foxp3<sup>+</sup> regulatory T cells are associated with better prognosis in triple-negative breast cancer. Breast Cancer Res Treat. 2017 May;163(1):21-35.
2017 Krishnamurti U Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers. Hum Pathol. 2017 Jun;64:7-12.
2017 Lean-Ferre RA Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat. 2017 Sep 14. doi: 10.1007/s10549-017-4499-7. [Epub ahead of print]
2017 Burugu S LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. Ann Oncol. 2017 Sep 25. doi: 10.1093/annonc/mdx557.                                       [Epub ahead of print]
2017 Adams TA Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer. Mod Pathol. 2017 Oct 6. doi: 10.1038/modpathol.2017.126.                                                [Epub ahead of print]
2017 Wang K The CD4/CD8 Ratio of Tumor-infiltrating Lymphocytes at the Tumor-host Interface Has Prognostic Value in Triple Negative Breast Cancer. Hum Pathol. 2017 Oct 6. doi: 10.1016/j.humpath.2017.09.012.                                               [Epub ahead of print]
2017 Liu X Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers. Oncologist. 2017 Nov;22(11):1316-1324. doi: 10.1634/theoncologist.2017-0029. Epub 2017 Jul 12.

Triple Negative Breast Cancer (TNBC), Early Stage, NEOADJUVANT Setting

TILs as a Predictor of Response (pre-treatment)

Year First author Full title Journal, year, volume, issue, pages (copy-paste from PubMed)
2010 Denkert C Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010 Jan 1;28(1):105-13.
2011 West NR Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13(6):R126.
2012 Ono M Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012 Apr;132(3):793-805.
2013 Lee HJ Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer. 2013 Mar;16(1):32-9.
2013 Seo AN Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013 Nov 12;109(10):2705-13.
2013 Issa-Nummer Y Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer–a substudy of the neoadjuvant GeparQuinto trial. PLoS One. 2013 Dec 2;8(12):e79775.
2014 Nabholtz JM Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. Ann Oncol. 2014 Aug;25(8):1570-7.
2014 Miyashita M Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2014 Dec;148(3):525-34.
2014 Brown JR Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2014 Dec 1;20(23):5995-6005.
2015 Denkert C Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015 Mar 20;33(9):983-91.
2015 Wimberly H PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res. 2015 Apr;3(4):326-32.
2015 Lee HJ Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes. Breast Cancer Res Treat. 2015 Jun;151(3):619-27.
2016 Ali HR Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res. 2016 Feb 16;18(1):21.
2016 Nabholtz JM Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer. Int J Cancer. 2016 May 1;138(9):2274-80.
2016 Asano Y Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer. Br J Surg. 2016 Jun;103(7):845-54.
2016 Hida AI Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies. Breast Cancer Res Treat. 2016 Jul;158(1):1-9.
2017 Song IH Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer. Cancer Res Treat. 2017 Apr;49(2):399-407.
2017 Kitano A Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. ESMO Open. 2017 May 2;2(2):e000150.
2017 McLemore LE An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer. Appl Immunohistochem Mol Morphol. 2017 Apr 18.
2017 Jovanovic B A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Clin Cancer Res. 2017 Aug 1;23(15):4035-4045.
2017 Ali HR Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial. Ann Oncol. 2017 Aug 1;28(8):1832-1835.
2017 Herero-Vicent C Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy. Ecancermedicalscience. 2017 Aug 15;11:759.
2017 Nuciforo P A predictive model of pathological response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Ann Oncol. 2017 Oct 12. doi: 10.1093/annonc/mdx647. [Epub ahead of print]

TILs as a Prognostic Factor (pre-treatment)

Year First author Full title Journal, year, volume, issue, pages (copy-paste from PubMed)
2016 Hida AI Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies. Breast Cancer Res Treat. 2016 Jul;158(1):1-9.
2017 Rao N Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy. Chemotherapy. 2017;62(4):246-255.
2017 Tomioka N The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Breast Cancer. 2017 May 9.
2017 Herero-Vicent C Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy. Ecancermedicalscience. 2017 Aug 15;11:759.

Post-treatment (TILs in post-neoadjuvant RESIDUAL DISEASE)

Year First author Full title Journal, year, volume, issue, pages (copy-paste from PubMed)
2014 Dieci MV Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014 Mar;25(3):611-8.
2015 Dieci MV Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2015 Jul;26(7):1518.
2015 Miyashita M Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res. 2015 Sep 4;17:124.
2016 Loi S RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clin Cancer Res. 2016 Mar 15;22(6):1499-509.
2017 Chen S PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. Int J Cancer. 2017 Mar 15;140(6):1384-1395.
2017 Pelekanou V Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. Breast Cancer Res. 2017 Aug 7;19(1):91.

HER2+ Breast Cancer, Early Stage, ADJUVANT Setting

Year First author Full title Journal, year, volume, issue, pages (copy-paste from PubMed)
2010 de Kruijf EM The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res. 2010 Feb 15;16(4):1272-80.
2011 Mahmoud SM An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat. 2011 May;127(1):99-108.
2011 Mahmoud SM Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011 May 20;29(15):1949-55.
2013 Mahmoud SM The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat. 2012 Apr;132(2):545-53.
2012 Mohamed ZM The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2012 Aug 21;107(5):864-73.
2012 Liu F Peritumoral FOXP3⁺ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3⁺ regulatory T cell is prognostic predictor of breast cancer patients. Breast Cancer Res Treat. 2012 Sep;135(2):459-67.
2013 Muenst S The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013 Jun;139(3):667-76.
2013 Mohammed ZM The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2013 Sep 17;109(6):1676-84.
2013 Gu-Trantien C CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013 Jul;123(7):2873-92.
2013 de Kruijf EM Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients. Breast Cancer Res Treat. 2013 Nov;142(2):355-64.
2014 Tsang JY Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers. Breast Cancer Res Treat. 2014 Jan;143(1):1-9.
2014 Loi S Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014 Aug;25(8):1544-50.
2014 Ali HR Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014 Aug;25(8):1536-43.
2014 Schalper KA In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014 May 15;20(10):2773-82.
2014 Liu S Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res. 2014 Sep 6;16(5):432.
2014 Kim S Zonal difference and prognostic significance of foxp3 regulatory T cell infiltration in breast cancer. J Breast Cancer. 2014 Mar;17(1):8-17.
2014 Chen Z Intratumoral CD8⁺ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. PLoS One. 2014 Apr 17;9(4):e95475.
2015 Quigley D Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. Mol Cancer Res. 2015 Mar;13(3):493-501.
2015 Dieci MV Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol. 2015 Aug;26(8):1698-704.
2015 Lee HJ Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab. Am J Clin Pathol. 2015 Aug;144(2):278-88.
2016 Mulligan AM Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer. Cancer Immunol Res. 2016 Jan;4(1):41-8.
2016 Park IH Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. Clin Breast Cancer. 2016 Feb;16(1):51-8.
2016 Perez A Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. JAMA Oncol. 2016 Jan;2(1):56-64.
2016 Kotoula V Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. Oncotarget. 2016 Jan 26;7(4):5074-87.
2016 Park IH Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. Clin Breast Cancer. 2016 Feb;16(1):51-8.
2016 Buisseret L Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncoimmunology. 2016 Dec 14;6(1):e1257452.
2017 Chung YR Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status. Breast Cancer Res Treat. 2017 Feb;161(3):409-420.
2017 Tsang YI PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. Breast Cancer Res Treat. 2017 Feb;162(1):19-30.
2017 Green AR Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers. Cancer Immunol Res. 2017 Apr;5(4):292-299.
2017 Kim A Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. Sci Rep. 2017 Sep 15;7(1):11671.
2017 Burugu S LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. Ann Oncol. 2017 Sep 25. doi: 10.1093/annonc/mdx557.                                       [Epub ahead of print]
2017 Liu X Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers. Oncologist. 2017 Nov;22(11):1316-1324. doi: 10.1634/theoncologist.2017-0029. Epub 2017 Jul 12.
2017 Luen SJ & Loi S Investigating the role of tumor-infiltrating lymphocytes in advanced HER2-positive breast cancer. Chin Clin Oncol. 2017 Nov 14. pii: cco.2017.10.06. doi: 10.21037/cco.2017.10.06. [Epub ahead of print]
2017 Criscitiello C Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. Eur J Cancer. 2017 Nov 15;87:164-171. doi: 10.1016/j.ejca.2017.10.011. [Epub ahead of print]

HER2+ Breast Cancer, Early Stage, NEOADJUVANT Setting

TILs as a Predictor of Response (pre-treatment)

Year First author Full title Journal, year, volume, issue, pages (copy-paste from PubMed)
2013 Lee HJ Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer. 2013 Mar;16(1):32-9.
2013 Gu-Trantien C CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013 Jul;123(7):2873-92.
2014 Brown JR Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2014 Dec 1;20(23):5995-6005.
2015 Denkert C Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015 Mar 20;33(9):983-91.
2015 Wimberly H PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res. 2015 Apr;3(4):326-32.
2015 Salgado R Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA Oncol. 2015 Jul;1(4):448-54.
2015 Hanusch C Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70). Clin Cancer Res. 2015 Jul 1;21(13):2924-31.
2015 Liu S Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015 Nov;154(2):239-49.
2015 Bianchini G Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. Ann Oncol. 2015 Dec;26(12):2429-36.
2016 Ali HR Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res. 2016 Feb 16;18(1):21.
2016 Asano Y Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer. Br J Surg. 2016 Jun;103(7):845-54.
2016 Hida AI Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies. Breast Cancer Res Treat. 2016 Jul;158(1):1-9.
2016 Park JH Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers. Cancer Chemother Pharmacol. 2016 Oct;78(4):685-95.
2016 Dieci MV Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. Ann Oncol. 2016 Oct;27(10):1867-73.
2016 Ingold-Heppner B Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. Clin Cancer Res. 2016 Dec 1;22(23):5747-5754.
2017 Song IH Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer. Cancer Res Treat. 2017 Apr;49(2):399-407.
2017 Kitano A Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. ESMO Open. 2017 May 2;2(2):e000150.
2017 Luen SJ & Loi S Investigating the role of tumor-infiltrating lymphocytes in advanced HER2-positive breast cancer. Chin Clin Oncol. 2017 Nov 14. pii: cco.2017.10.06. doi: 10.21037/cco.2017.10.06. [Epub ahead of print]
2017 Inoue H Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer. Breast Cancer. 2017 Nov 28. doi: 10.1007/s12282-017-0822-8. [Epub ahead of print]
2017 Hou Y Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy. Clin Breast Cancer. 2017 Nov 9. pii: S1526-8209(17)30604-3. doi: 10.1016/j.clbc.2017.11.001. [Epub ahead of print]

TILs as a Prognostic Factor (pre-treatment)

Year First author Full title Journal, year, volume, issue, pages (copy-paste from PubMed)
2015 Salgado R Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA Oncol. 2015 Jul;1(4):448-54.
2015 Liu S Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015 Nov;154(2):239-49.
2016 Hida AI Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies. Breast Cancer Res Treat. 2016 Jul;158(1):1-9.
2016 Ingold-Heppner B Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. Clin Cancer Res. 2016 Dec 1;22(23):5747-5754.

Post-treatment (TILs in post-neoadjuvant RESIDUAL DISEASE)

Year First author Full title Journal, year, volume, issue, pages (copy-paste from PubMed)
2011 Ladoire S In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol. 2011 Jul;224(3):389-400.
2011 Ladoire S T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br J Cancer. 2011 Jul 26;105(3):366-71.
2017 Chen S PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. Int J Cancer. 2017 Mar 15;140(6):1384-1395.
2017 Pelekanou V Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. Breast Cancer Res. 2017 Aug 7;19(1):91.
2017 Hamy AS Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer. Ann Oncol. 2017 Sep 1;28(9):2233-2240.

HR+/HER2- Breast Cancer, Early Stage, ADJUVANT Setting

Year First author Full title Journal, year, volume, issue, pages (copy-paste from PubMed)
2010 de Kruijf EM The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res. 2010 Feb 15;16(4):1272-80.
2011 Mahmoud SM An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat. 2011 May;127(1):99-108.
2011 Mahmoud SM Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011 May 20;29(15):1949-55.
2011 Baker K Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology. 2011 Jun;58(7):1107-16.
2012 Mahmoud SM The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat. 2012 Apr;132(2):545-53.
2012 Mohamed ZM The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2012 Aug 21;107(5):864-73.
2012 Ma C Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer. J Immunol. 2012 Nov 15;189(10):5029-36.
2013 Loi S Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013 Mar 1;31(7):860-7.
2013 Muenst S The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013 Jun;139(3):667-76.
2013 Gu-Trantien C CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013 Jul;123(7):2873-92.
2013 Mohammed ZM The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2013 Sep 17;109(6):1676-84.
2013 de Kruijf EM Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients. Breast Cancer Res Treat. 2013 Nov;142(2):355-64.
2014 Tsang JY Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers. Breast Cancer Res Treat. 2014 Jan;143(1):1-9.
2014 Kim S Zonal difference and prognostic significance of foxp3 regulatory T cell infiltration in breast cancer. J Breast Cancer. 2014 Mar;17(1):8-17.
2014 Chen Z Intratumoral CD8⁺ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. PLoS One. 2014 Apr 17;9(4):e95475.
2014 Schalper KA In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014 May 15;20(10):2773-82.
2014 Ali HR Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014 Aug;25(8):1536-43.
2014 Liu S Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res. 2014 Sep 6;16(5):432.
2015 Engels CC The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis. Breast Cancer Res Treat. 2015 Feb;149(3):587-96.
2015 Quigley D Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. Mol Cancer Res. 2015 Mar;13(3):493-501.
2015 Dieci MV Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol. 2015 Aug;26(8):1698-704.
2016 Mulligan AM Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer. Cancer Immunol Res. 2016 Jan;4(1):41-8.
2016 Park IH Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. Clin Breast Cancer. 2016 Feb;16(1):51-8.
2016 KotoulaV Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. Oncotarget. 2016 Jan 26;7(4):5074-87.
2016 Park IH Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. Clin Breast Cancer. 2016 Feb;16(1):51-8.
2016 Buisseret L Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncoimmunology. 2016 Dec 14;6(1):e1257452.
2017 Chung YR Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status. Breast Cancer Res Treat. 2017 Feb;161(3):409-420.
2017 Green AR Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers. Cancer Immunol Res. 2017 Apr;5(4):292-299.
2017 McLemore LE An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer. Appl Immunohistochem Mol Morphol. 2017 Apr 18.
2017 Krishnamurti U Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers. Hum Pathol. 2017 Jun;64:7-12.
2017 Liu X Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers. Oncologist. 2017 Nov;22(11):1316-1324. doi: 10.1634/theoncologist.2017-0029. Epub 2017 Jul 12.

HR+/HER2- Breast Cancer, Early Stage, NEOADJUVANT Setting

TILs as a Predictor of Response (pre-treatment)

Year First author Full title Journal, year, volume, issue, pages (copy-paste from PubMed)
2012 Yamaguchi R Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol. 2012 Oct;43(10):1688-94.
2012 Chan MS Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients–an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients. Int J Biol Markers. 2012 Dec 27;27(4):e295-304.
2013 Lee HJ Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer. 2013 Mar;16(1):32-9.
2013 Seo AN Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013 Nov 12;109(10):2705-13.
2013 Issa-Nummer Y Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer–a substudy of the neoadjuvant GeparQuinto trial. PLoS One. 2013 Dec 2;8(12):e79775.
2014 Brown JR Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2014 Dec 1;20(23):5995-6005.
2014 Wimberly H PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res. 2015 Apr;3(4):326-32.
2017 Krishnamurti U Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers. Hum Pathol. 2017 Jun;64:7-12.
2017 Dieci MV Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials. Breast Cancer Res Treat. 2017 Jun;163(2):295-302.
2017 Ali HR Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial. Ann Oncol. 2017 Aug 1;28(8):1832-1835.

TILs as a Prognostic Factor (pre-treatment)

Post-treatment (TILs in post-neoadjuvant RESIDUAL DISEASE)

Year First author Full title Journal, year, volume, issue, pages (copy-paste from PubMed)
2017 Chen S PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. Int J Cancer. 2017 Mar 15;140(6):1384-1395.
2017 Pelekanou V Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. Breast Cancer Res. 2017 Aug 7;19(1):91.
2018 Heindl A Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer. J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx137.

META-ANALYSES and SIMILAR (all BC subtypes)

Year First author Full title Journal, year, volume, issue, pages (copy-paste from PubMed)
2014 Ibrahim EM The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. Breast Cancer Res Treat. 2014 Dec;148(3):467-76.
2014 Mao Y The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One. 2014 Dec 12;9(12):e115103.
2015 Stoll G Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies. Oncotarget. 2015 May 20;6(14):11894-909.
2015 Shang B Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015 Oct 14;5:15179.
2015 Jiang D Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis. BMC Cancer. 2015 Oct 17;15:727.
2016 Yu X Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. Clin Transl Oncol. 2016 May;18(5):497-506.
2016 Carbognin L Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. Oncologist. 2016 Mar;21(3):283-91.
2016 Mao Y The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis. PLoS One. 2016 Apr 13;11(4):e0152500.
2016 Wang K Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis. Oncotarget. 2016 Jul 12;7(28):44288-44298.
2016 Shou J Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis. BMC Cancer. 2016 Aug 26;16:687.
2017 Zhao T Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis. PLoS One. 2017 Apr 28;12(4):e0176822.
2017 Solinas C Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. Cancer Treat Rev. 2017 Jun;57:8-15.
2017 Qian F High tumor-infiltrating FoxP3<sup>+</sup> T cells predict poor survival in estrogen receptor-positive breast cancer: A meta-analysis. Eur J Surg Oncol. 2017 Jul;43(7):1258-1264.
2017 Buisseret L Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. Mod Pathol. 2017 Sep;30(9):1204-1212.
2017 Stovgaard ES Triple negative breast cancer – prognostic role of immune-related factors: a systematic review. Acta Oncol. 2017 Nov 23: 1-9 doi: 10.1080/0284186X.2017.1400180. [Epub ahead of print]
2017 Xu T The Predictive and Prognostic Role of Stromal Tumor-infiltrating Lymphocytes in HER2-positive Breast Cancer with Trastuzumab-based Treatment: a Meta-analysis and Systematic Review. J Cancer. 2017 Oct 17;8(18):3838-3848. doi: 10.7150/jca.21051. eCollection 2017.

Metastatic Breast Cancer

Year First author Full title Journal, year, volume, issue, pages (copy-paste from PubMed)
2010 Wright SE Number of treatment cycles influences development of cytotoxic T cells in metastatic breast cancer patients – a phase I/II study. Immunol Invest. 2010;39(6):570-86.
2011 Ciampricotti M Development of metastatic HER2(+) breast cancer is independent of the adaptive immune system. J Pathol. 2011 May;224(1):56-66.
2013 Cimino-Mathews A Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum Pathol. 2013 Oct;44(10):2055-63.
2015 Harter PN Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Oncotarget. 2015 Dec 1;6(38):40836-49.
2016 Cimino-Mathews A PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol. 2016 Jan;47(1):52-63.
2016 Duchnowska R Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Breast Cancer Res. 2016 Apr 27;18(1):43.
2016 Sobottka P Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. Oncoimmunology. 2016 May 5;5(6):e1153208.
2016 Ogiya R Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. Cancer Sci. 2016 Dec;107(12):1730-1735.
2017 Luen SJ Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 2017 Jan;18(1):52-62.
2017 Kashiwagi S Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer. PLoS One. 2017 Feb 6;12(2):e0170634.
2017 Mansour M Advancing Immunotherapy in Metastatic Breast Cancer. Curr Treat Options Oncol. 2017 Jun;18(6):35.
2017 Montagna E Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. Breast. 2017 Aug;34:83-88.
2017 Liu S Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2017 Nov 9;3(11):e172085. doi: 10.1001/jamaoncol.2017.2085. Epub 2017 Nov 9.

Breast Cancer In Situ

Year First author Full title Journal, year, volume, issue, pages (copy-paste from PubMed)
2013 Lal A FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. Breast Cancer Res Treat. 2013 Jun;139(2):381-90.
2016 Thompson E The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol. 2016 Mar;29(3):249-58.
2016 Kim A An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes. Am J Clin Pathol. 2016 Jul;146(1):137-44.
2016 Semeraro M The ratio of CD8<sup>+</sup>/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma <i>in situ</i>. Oncoimmunology. 2016 Aug 18;5(10):e1218106.
2016 Morita M Two progressive pathways of microinvasive carcinoma: low-grade luminal pathway and high-grade HER2 pathway based on high tumour-infiltrating lymphocytes. J Clin Pathol. 2016 Oct;69(10):890-8.
2017 Campbell MJ Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2017 Jan;161(1):17-28.
2017 Pruneri G The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Ann Oncol. 2017 Feb 1;28(2):321-328.
2017 Miligy I Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. Histopathology. 2017 Aug;71(2):258-268.
2017 Hendry S Relationship of the Breast Ductal Carcinoma <i>In Situ</i> Immune Microenvironment with Clinicopathological and Genetic Features. Clin Cancer Res. 2017 Sep 1;23(17):5210-5217.
2017 Polonia A Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer. J Clin Pathol. 2017 Oct;70(10):860-867.
2017 Gil del Alcazar CR Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer Discov. 2017 Oct;7(10):1098-1115.